Profile data is unavailable for this security.
About the company
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
- Revenue in USD (TTM)14.61m
- Net income in USD-133.03m
- Incorporated2015
- Employees231.00
- LocationGritstone bio Inc5959 HORTON STREET, SUITE 300EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 871-6100
- Fax+1 (510) 597-1488
- Websitehttps://gritstonebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENDRA Life Sciences Inc | 0.00 | -9.57m | 2.97m | 21.00 | -- | 0.0264 | -- | -- | -1,597.14 | -1,597.14 | 0.00 | 217.30 | 0.00 | -- | -- | 0.00 | -97.17 | -132.00 | -117.34 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
| Entero Therapeutics Inc | 0.00 | -9.69m | 3.00m | 15.00 | -- | 0.2032 | -- | -- | -15.29 | -15.87 | 0.00 | 24.07 | 0.00 | -- | -- | 0.00 | -20.88 | -295.92 | -26.29 | -1,599.51 | -- | -- | -- | -- | -- | -2,709.72 | 0.0025 | -- | -- | -- | -7.55 | -- | -- | -- |
| Qualigen Therapeutics Inc | 0.00 | -9.27m | 3.03m | 4.00 | -- | -- | -- | -- | -82.94 | -87.60 | 0.00 | -22.25 | 0.00 | -- | -- | 0.00 | -134.64 | -- | -- | -- | -- | -- | -- | -- | -- | -9.64 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| Aditxt Inc | 329.75k | -43.31m | 3.04m | 47.00 | -- | 0.0026 | -- | 9.22 | -3,088.09 | -3,088.09 | 12.12 | 131.74 | 0.0185 | 0.6082 | 0.8393 | 7,015.96 | -242.33 | -192.78 | -1,548.63 | -321.59 | -46.09 | -- | -13,105.77 | -7,208.65 | 0.0458 | -3.53 | 0.5084 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 4.60m | -7.68m | 3.10m | 13.00 | -- | 0.2252 | -- | 0.675 | -1.33 | -1.33 | 0.6027 | 1.03 | 0.3546 | 2.44 | 14.99 | -- | -59.20 | -92.09 | -69.92 | -113.17 | 23.94 | -- | -166.94 | -543.29 | 3.78 | -- | 0.00 | -- | 11.18 | -- | 3.42 | -- | -19.10 | -- |
| Gritstone bio Inc | 14.61m | -133.03m | 3.19m | 231.00 | -- | 0.1433 | -- | 0.2183 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.19m | 5.00 | -- | 1.47 | -- | 6.29 | -4.95 | -4.95 | 0.5919 | 1.79 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Talis Biomedical Corp | 408.00k | -51.03m | 3.21m | 99.00 | -- | 0.066 | -- | 7.86 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Theriva Biologics Inc | 0.00 | -22.27m | 3.23m | 21.00 | -- | 1.23 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Tharimmune Inc | 0.00 | -8.88m | 3.24m | 2.00 | -- | 0.3566 | -- | -- | -55.46 | -55.46 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -138.06 | -- | -181.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -11.60m | 3.28m | 10.00 | -- | 1.56 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Oncternal Therapeutics Inc | 2.16m | -34.58m | 3.37m | 27.00 | -- | 0.3685 | -- | 1.56 | -11.70 | -11.70 | 0.7314 | 3.09 | 0.0735 | -- | -- | 80,037.04 | -117.61 | -49.40 | -146.53 | -54.51 | -- | -- | -1,599.95 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -523.87k | 3.39m | 0.00 | -- | 0.3737 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Gritstone bio Inc's reporting currency: US Dollar USD
15.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Oct 2024 | 4.64m | 3.93% |
| Alyeska Investment Group LPas of 30 Jun 2024 | 3.46m | 2.93% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 3.03m | 2.57% |
| Fidelity Management & Research Co. LLCas of 03 Oct 2024 | 1.75m | 1.48% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 1.41m | 1.19% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.25m | 1.06% |
| DWS Investments (UK) Ltd.as of 03 Oct 2024 | 1.25m | 1.06% |
| Jane Street Capital LLCas of 30 Jun 2024 | 703.32k | 0.60% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 596.06k | 0.51% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Jul 2024 | 372.28k | 0.32% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
